Savolitinib vs. Sunitinib in MET-driven PRCC.
← catalyst calendarSponsored by AstraZeneca (industry) · AZN — their whole pipeline →. With Hutchison Medipharma Limited.
Phase
Phase 3
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
60actual
Sites
59
Countries
Brazil, France, Italy +4
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2017-07-25 | actual | When the study began enrolling |
| Primary completion | 2019-08-18 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-12-31 | estimated | The whole study's end, after follow-up |
| First posted | 2017-03-27 | actual | When this record first appeared on the registry |
| Results posted | 2020-07-10 | actual | When the sponsor posted results to the registry |
| Record updated | 2026-07-14 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Carcinoma
- Carcinoma, Renal Cell
- Kidney Neoplasms
- Urologic Neoplasms
- Kidney Diseases
- Neoplasms by Site
- Enzyme Inhibitors
- Protein Kinase Inhibitors
Interventions
- Drug: Savolitinib — also filed as AZD6094 (HMPL-504)/Volitinib
- Drug: Sunitinib
Primary outcome
what the primary-completion date above is the date OFProgression Free Survival (PFS) by Blinded Independent Central Review (BICR)
measured RECIST tumour assessments every 6 weeks from randomisation until disease progression as defined by Recist 1.1 and confirmed by BICR.
Posted documents
hosted by the registry — we link, never re-serveStudy Protocolposted 2018-12-19 · 2.7 MB · Prot_004.pdf
Statistical Analysis Planposted 2019-08-28 · 718 KB · SAP_000.pdf
Publications
- PMID 32469384 — linked by the registry
- PMID 32203306 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed